FDA Accepts QTORIN Rapamycin NDA for Microcystic Lymphatic Malformations

Palvella Therapeutics announced FDA acceptance of its QTORIN rapamycin application with a focused launch plan ahead of a February 28, 2027 priority review deadline. The development progress increases the likelihood of a first-ever therapy for a rare disease, though no data on sales figures or immediate executive impacts were provided in the filing.